Sponsor Pipeline

Merus B.V. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
4
Active Trials
3
Recruiting
2
Phase 3
6
Disease Areas
4
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-30 NCT03526835
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors		 Primary endpoint(s) modified
2026-07-30 NCT03526835
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors		 Trial sites expanded: 45 -> 54 locations
2026-07-30 NCT03526835
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors		 date change Primary completion pushed: 2025-11 -> 2028-05
2026-07-30 NCT03526835
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors		 date change Completion pushed: 2027-11 -> 2028-11
Active Trials by Phase
Phase 3
2
Phase 1/2
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06525220 A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in… Head and Neck Squamous Cell Carcinoma Recruiting
NCT06496178 A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy… Head and Neck Squamous Cell Carcinoma Recruiting
Phase 1/2
NCT03526835 A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors Advanced/Metastatic Solid Tumors Recruiting
NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody… Non-Small Cell Lung Cancer Metastatic Active, Not Recruiting
Disease Areas
Head & Neck Cancer (4) Non-Small Cell Lung Cancer (NSCLC) (2) Colorectal Cancer (2) Gastric Cancer (2) Esophageal Cancer (1) Lung Cancer (1)
Get alerts when Merus B.V.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free